Nurix therapeutics announces ind clearance for detil-0255, a drug-enhanced autologous t cell therapy for the potential treatment of a variety of solid tumors

Food and drug administration clears detil-0255 to initiate phase 1 clinical trial
NRIX Ratings Summary
NRIX Quant Ranking